<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="transplant recipients. Neuraminidase inhibitor therapy has been suggested for influenza," exact="ribavirin" post="for RSV, and cidofovir for adenovirus infections. However, there"/>
 <result pre="therapy has been suggested for influenza, ribavirin for RSV, and" exact="cidofovir" post="for adenovirus infections. However, there is no evidence supporting"/>
 <result pre="transplant recipients, and patients with chronic lymphocytic leukaemia treated with" exact="fludarabine" post="combined with CD52 monoclonal antibodies [88, 89]. In allogeneic"/>
 <result pre="channel inhibitors and neuraminidase inhibitors. The M2 ion channel inhibitors," exact="amantadine" post="and rimantadine, act by inhibiting the M2 protein needed"/>
 <result pre="influenza A strains [122]. The neuraminidase inhibitors (Table 21.3), oral" exact="oseltamivir" post="and inhaled zanamivir, are sialic acid analogues that competitively"/>
 <result pre="every 2 weeks according to the clinical response cHyperhydratation and" exact="probenecide" post="may help to prevent cidofovir nephrotoxicity dHaemolytic anaemia may"/>
 <result pre="the clinical response cHyperhydratation and probenecide may help to prevent" exact="cidofovir" post="nephrotoxicity dHaemolytic anaemia may be readily controlled by blood"/>
 <result pre="drug for Paramyxoviridae infection (Table 21.3). The efficacy of aerosolized" exact="ribavirin" post="was variable in uncontrolled cohorts of patients with RSV-related"/>
 <result pre="132]. Again, the results must be interpreted with caution. Early" exact="ribavirin" post="therapy, introduced before the onset of respiratory failure, seemed"/>
 <result pre="al. [132]. This observation led some authors to evaluate pre-emptive" exact="ribavirin" post="therapy, characterised by ribavirin treatment of RSV URTI to"/>
 <result pre="led some authors to evaluate pre-emptive ribavirin therapy, characterised by" exact="ribavirin" post="treatment of RSV URTI to prevent progression to pneumonia"/>
 <result pre="et al. is the only randomised controlled trial evaluating pre-emptive" exact="ribavirin" post="therapy in patients with RSV infection [133]. Unfortunately, the"/>
 <result pre="enrol a sufficient number of patients to produce conclusions. Intravenous" exact="ribavirin" post="has also been evaluated and found unhelpful [29, 135]."/>
 <result pre="has also been evaluated and found unhelpful [29, 135]. Combining" exact="ribavirin" post="with intravenous immunoglobulins or RSV-specific immunoglobulins produced variable levels"/>
 <result pre="was evaluated only in a small cohort [138]. In vitro," exact="ribavirin" post="exhibits mild antiviral activity against PIV [58]. No clear"/>
 <result pre="antiviral activity against PIV [58]. No clear efficacy of aerosolized" exact="ribavirin" post="was found in small, uncontrolled cohorts of patients with"/>
 <result pre="cohorts of patients with HM [34, 139]. Early initiation of" exact="ribavirin" post="therapy has been proposed to enhance efficacy [140]. No"/>
 <result pre="titres of PIV-specific immunoglobulins. An in vitro study suggests that" exact="ribavirin" post="may be of interest for treating human MPV-related pneumonia,"/>
 <result pre="treatment of adenoviral disease in patients with HM. Ribavirin and" exact="cidofovir" post="have been suggested for the treatment of adenoviral infections,"/>
 <result pre="uncontrolled cohort studies are available to support their use. Intravenous" exact="ribavirin" post="therapy failed to demonstrate benefits in available studies [89,"/>
 <result pre="also been reported in some small series [155, 156]. Early" exact="cidofovir" post="treatment seems associated with a better outcome [151]. Weekly"/>
 <result pre="screening for adenovirus viraemia has been suggested to guide pre-emptive" exact="cidofovir" post="therapy [91–94, 153, 157]. The exact threshold above which"/>
 <result pre="therapy [91–94, 153, 157]. The exact threshold above which pre-emptive" exact="cidofovir" post="therapy should be initiated is unknown. Randomised controlled trials"/>
 <result pre="proposed to prevent common respiratory virus infections. Intravenous immunoglobulins and" exact="palivizumab" post="have been suggested for RSV infection prevention, but have"/>
 <result pre="have not been evaluated in patients with HM. Prophylactic post-exposure" exact="oseltamivir" post="therapy is currently recommended in patients with HM [176]."/>
 <result pre="HSCT recipients [177]. Considering the lack of proven benefits of" exact="oseltamivir" post="therapy and the growing concern about the emergence of"/>
 <result pre="the growing concern about the emergence of oseltamivir-resistant influenza strains," exact="oseltamivir" post="therapy should be carefully evaluated before it is suggested"/>
 <result pre="the 20th century: a period analysisLancet200236093401131113512387961 4.CoiffierBet al.CHOP chemotherapy plus" exact="rituximab" post="compared with CHOP alone in elderly patients with diffuse"/>
 <result pre="95.BrunoBet al.Adenovirus infection in hematopoietic stem cell transplantation: effect of" exact="ganciclovir" post="and impact on survivalBiol Blood Marrow Transplant20039534135212766884 96.HaleGAet al.Adenovirus"/>
 <result pre="recipientsTranspl Infect Dis200911429830319453994 121.Jefferson TO et al (2002) Amantadine and" exact="rimantadine" post="for preventing and treating influenza A in adults. Cochrane"/>
 <result pre="Trialists) Study GroupRandomised trial of efficacy and safety of inhaled" exact="zanamivir" post="in treatment of influenza A and B virus infectionsLancet19983529144187718819863784"/>
 <result pre="A and B virus infectionsLancet19983529144187718819863784 124.NicholsonKGet al.Efficacy and safety of" exact="oseltamivir" post="in treatment of acute influenza: a randomised controlled trial."/>
 <result pre="GroupLancet200035592181845185010866439 125.TreanorJJet al.Efficacy and safety of the oral neuraminidase inhibitor" exact="oseltamivir" post="in treating acute influenza: a randomised controlled trial. US"/>
 <result pre="US Oral Neuraminidase Study GroupJAMA200028381016102410697061 126.MontoASWebsterAKeeneORandomized, placebo-controlled studies of inhaled" exact="zanamivir" post="in the treatment of influenza A and B: pooled"/>
 <result pre="efficacy analysisJ Antimicrob Chemother199944Suppl B232910877459 127.AokiFYet al.Early administration of oral" exact="oseltamivir" post="increases the benefits of influenza treatmentJ Antimicrob Chemother200351112312912493796 128.McGeerAet"/>
 <result pre="bone marrow transplantationBone Marrow Transplant200434211111415094755 132.WhimbeyEet al.Combination therapy with aerosolized" exact="ribavirin" post="and intravenous immunoglobulin for respiratory syncytial virus disease in"/>
 <result pre="recipientsBone Marrow Transplant19951633933998535312 133.BoeckhMet al.Randomized controlled multicenter trial of aerosolized" exact="ribavirin" post="for respiratory syncytial virus upper respiratory tract infection in"/>
 <result pre="marrow transplant recipients with breast cancer: combination therapy with aerosolized" exact="ribavirin" post="and parenteral immunoglobulinsBone Marrow Transplant200128327127511535995 135.LewinsohnDMet al.Phase I study"/>
 <result pre="parenteral immunoglobulinsBone Marrow Transplant200128327127511535995 135.LewinsohnDMet al.Phase I study of intravenous" exact="ribavirin" post="treatment of respiratory syncytial virus pneumonia after marrow transplantationAntimicrob"/>
 <result pre="adult blood and marrow transplant recipients: combination therapy with aerosolized" exact="ribavirin" post="and intravenous immunoglobulinBone Marrow Transplant200025775175510745261 138.BoeckhMet al.Phase 1 evaluation"/>
 <result pre="al.Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody" exact="palivizumab" post="in recipients of hematopoietic stem cell transplantsJ Infect Dis2001184335035411443562"/>
 <result pre="3 infections in hematopoetic stem cell transplant recipients: response to" exact="ribavirin" post="therapyClin Infect Dis20003161516151811096028 141.WydePRet al.Comparison of the inhibition of"/>
 <result pre="the inhibition of human metapneumovirus and respiratory syncytial virus by" exact="ribavirin" post="and immune serum globulin in vitroAntiviral Res2003601515914516921 142.BordigoniPet al.Treatment"/>
 <result pre="adenovirus hepatitis following unrelated bone marrow transplantation: failure of intravenous" exact="ribavirin" post="therapyBone Marrow Transplant199923111209121110382964 144.GavinPJKatzBZIntravenous ribavirin treatment for severe adenovirus"/>
 <result pre="marrow transplantation: failure of intravenous ribavirin therapyBone Marrow Transplant199923111209121110382964 144.GavinPJKatzBZIntravenous" exact="ribavirin" post="treatment for severe adenovirus disease in immunocompromised childrenPediatrics20021101 Pt"/>
 <result pre="treatment with intravenous ribavirinBone Marrow Transplant19931244094128275042 146.MannDet al.Failure of intravenous" exact="ribavirin" post="in the treatment of invasive adenovirus infection following allogeneic"/>
 <result pre="allogeneic bone marrow transplantation: a case reportJ Infect19983622272289570662 147.MiyamuraKet al.Successful" exact="ribavirin" post="therapy for severe adenovirus hemorrhagic cystitis after allogeneic marrow"/>
 <result pre="Marrow Transplant200025554554810713633 148.HoffmanJAet al.Adenoviral infections and a prospective trial of" exact="cidofovir" post="in pediatric hematopoietic stem cell transplantationBiol Blood Marrow Transplant20017738839411529489"/>
 <result pre="Transplant20017738839411529489 149.LegrandFet al.Early diagnosis of adenovirus infection and treatment with" exact="cidofovir" post="after bone marrow transplantation in childrenBone Marrow Transplant200127662162611319592 150.LjungmanPet"/>
 <result pre="Full textMed Mal Infect200535Suppl 4S24527316535783 177.VuDet al.Safety and tolerability of" exact="oseltamivir" post="prophylaxis in hematopoietic stem cell transplant recipients: a retrospective"/>
</results>
